Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: A phase II study

Japanese Journal of Clinical Oncology

Volumn 40, Issue 10, 2010, Pages 967-972

  Sumiyoshi, Yoshiteru ^a   Hashine, Katsuyoshi ^a   Kakehi, Yoshiyuki ^b   Yoshimura, Koji ^c   Satou, Takehumi ^d   Kuruma, Hidetoshi ^e   Namiki, Syunichi ^f   Shinohara, Nobuo ^g  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Dietary supplement; Expectant management; Prostate cancer

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANTIGEN EXPRESSION; ANXIETY; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSHROOM; MYCELIUM; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; TUMOR BIOPSY;

AGARICALES; AGED; AGED, 80 AND OVER; DIARRHEA; DIETARY SUPPLEMENTS; HUMANS; MALE; MIDDLE AGED; MYCELIUM; NEOPLASM STAGING; POLYSACCHARIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957697733     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq081     Document Type: Article

References (21)

1. NCCN Clinical Practice Guidelines in Oncology™. http://www.nccn.org/professionals/physician_gls/fguidelines.asp (1 February 2010, date last accessed).
2. Kakehi Y, Kamoto T, Sumiyoshi Y, Shiraishi T, Ogawa O, Suzukamo Y, et al. Prospective evaluation of selection criteria for active surveillancein Japanese patients with stage T1cN0M0 prostate cancer. Jpn. J Clin Oncol 2008;38:122-8.
3. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletany SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14
4. Jacobson JS, Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep 2001;3:448-52.
5. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23:2645-54.
6. Yoshimura K, Ichioka K, Terada N, Terai A, Arai Y. Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol 2003;8:26-30.
7. Yoshimura K, Sumiyoshi Y, Kamoto T, Ogawa O, Arai Y, Kakehi Y, et al. Transition behavior in the use of complementary and alternative medicine during follow-up after radical prostatectomy: a multicenter survey in Japan. Health. (in press).
8. Sumiyoshi Y, Hashine K, Koizumi T, Azuma K, Hyodo K. Use of complementary and alternative medicine in prostate cancer patients. Nippon Hinyokika Gakkai Zasshi 2003;94:328 (in Japanese).
9. Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 2005;55:33-8.
10. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-6.
11. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998;16:3649-55.
12. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 2005;104:176-82
13. Ansari MS, Gupta DNP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 2004;22:415-20
14. Jatori A, Burch P, Hillman D, Vanyo JM, Dakhill S, Nikcevich D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a phase II study from the North Central Cancer Treatment group. Urology 2007;69:289-94.
15. Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H. Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol 2009;8:43-51.
16. Ritz BW. Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr Rev 2008;66:526-31.
17. Matsui K, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 2002;37:78-86.
18. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology 2002;60:160-4.
19. Spierings ELH, Fujii H, Sun B, Walshe T. A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol 2007;53:536-9.
20. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EP, Raisin CJ, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005;174:1065-70.
21. Ghoneum M, Ninomiya Y, Torabi M, Gil G, Wojani A. Active hemicelluloses compound (AHCC) enhances NK cell activity of aged mice in vivo. FASEB J 1992;6:A1213.